Belfast’s Amply Secures $1.75Mn For AI Drug Discovery

The funding round was led by Twin Path Ventures, with support from Venture Science (US), Co-Fund NI, the British Business Bank, and QUBIS Limited.

AMPLY is a spin-out from Queen’s University Belfast, based on over 10 years of research from the Creevey Lab. It was founded by scientists Dr Ben Thomas, Dermot Tierney, and Prof Chris Creevey.

The company will use the funding to speed up drug development and move its discovery projects further along the preclinical stage.

According to Dr Ben Thomas, CEO and Chief Architect of AMPLY:

“Ten years ago, I began combining financial modeling expertise with computational biology to create a drug discovery platform.

Evolution has spent billions of years perfecting natural defence mechanisms, and now we're using AI to unlock this wisdom.”

He shared:

“At Queen's, I built AMPLY to tackle deadly diseases differently, creating technology that will save lives when current treatments fail."

AMPLY has built a powerful drug discovery platform that uses AI, Next Generation Sequencing, and Synthetic Biology to speed up finding treatments for diseases linked to genetic differences in people.

The platform can study biological molecules, find potential drug targets, and even bio-print real molecules that can be tested and improved in the lab quickly.

With its tool called AMPLYfolioAI, AMPLY's scientists are working to better understand complex diseases, create smarter, targeted medicines, and develop a process that is faster, cheaper, and can be done on a much larger scale than before.

Katie Lockwood, Partner at Twin Path, said:

“We're impressed by Amply's proprietary experimental dataset, their unique AI approach that incorporates human expertise, and their ability to validate AI discoveries through in vitro and in vivo testing.

The founding team exemplifies the cross-disciplinary expertise we seek in breakthrough AI investments.

Their application of AI to computational biology has already yielded impressive results that could transform drug discovery for complex diseases.”

About Amply

Amply is a company based in Gurugram, India, founded in 2021 by Anshul Goyal and Anshika Parihar. It builds AI-powered no-code tools that help businesses create workflows without needing to write code. The company is currently unfunded.